Расширенный поиск


Полный текст:


В статье представлена современная стратегия вторичной профилактики венозных тромбозов. Оценены польза и возможные риски при использовании пероральных антикоагулянтов. Оценена возможность назначения препаратов ацетилсалициловой кислоты при невозможности применения новых пероральных антикоагулянтов.

Об авторе

П. С. Лагута
Институт клинической кардиологии им. А. Л. Мясникова Российского кардиологического научно-производственного комплекса, Москва
Кандидат медицинских наук

Список литературы

1. Kearon C, Akl EA, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Guidelines (9th Edition). Chest, 2012, 141(Suppl): 419-494.

2. Konstantinides SV. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur. Heart J., 2014, 35: 3033-80.

3. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep vein thrombosis or pulmonary embolism. Thromb. Haemost., 2002, 88: 407-14.

4. Kearon C. National history of venous thromboembolism. Circulation, 2003, 107(1): 22-130.

5. Boutitie F, Pinede L, Schulman S et al. Influence of preceding duration of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrenceafter stopping therapy: analysis of individual participants’data from seven trials. BMJ, 2011, 342: d3036

6. . 6. Baglin T, Loddington R, Brown K. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet, 2003, 362: 523-26.

7. Iorio A, Kearon C, Filippucci E et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med, 2010, 170(19): 1710-16.

8. Hutten BA, Prins MH, Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol, 2000, 18(17): 3078-3083

9. . 9. Pinede, Ninet J, Duhaut P et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation, 2001, 103: 2453-60.

10. Grifoni S, Vanni S, Magazzini S et al. Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med, 2006, 166(19): 2151-56.

11. Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N. Engl. J. Med., 1997, 336: 393-8.

12. Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N. Engl. J. Med., 1999, 340: 901-7.

13. Palareti G, Cosmi B, Legnani C. et. al. D-dimer testing to determine the duration of oral anticoagulant therapy. N. Engl. J. Med., 2006, 355: 1780-9.

14. Ridker PM, Goldhaber SZ, Danielson et al. Longterm, low-intensity warfarin therapy for prevention of reccurent venous thromboembolism. N. Engl. J. Med., 2003, 348: 1425-34.

15. Schulman S, Kearon C, Kakkar AK et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med., 2013, 368(8): 709-718.

16. Bauersachs R, Berkowitz SD, Brenner В et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med., 2010, 363(26): 2499-2510.

17. Agnelli G, Buller H.R, Cohen A. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368(8): 699-708.

18. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet, 2000, 355: 1295-1302.

19. Grady D, Wenger NK, Herrington D et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med, 2000, 132: 689-96.

20. The ESPS 2 Group. European Stroke Prevention Study 2. Efficacy and safety data. Secondary endpoints. J Neurol Sci, 1997, 151: S27-S37.

21. McConnel H. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J., 2002, 324: 71-86.

22. Becattini C, Agnelli G, Schenone A et al. Aspirin for preventing the recurrence of venous thromboembolism. N. Engl. J. Med., 2012, 366: 1959-67.

23. Brighton TA, Eikelboom JW, Mann K et. al. Lowdose aspirin for preventing the recurrent venous thromboembolism. N. Engl. J. Med, 2012, 367: 19791987.

24. Kearon C, Akl EA, Ornelas J. Antithrombotic Therapy for VTE Disease. Chest Guideline and Expert Panel Report. Chest, 2016, 149(2): 315-352.

Для цитирования:


For citation:

Laguta P.S. NEW PROSPECTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOSIS. Aterotromboz = Atherothrombosis. 2016;(1):5-15. (In Russ.)

Просмотров: 786

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.

ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)